בליאומיצין PFI

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

BLEOMYCIN SULFATE

Disponível em:

MEGAPHARM LTD

Código ATC:

L01DC01

Forma farmacêutica:

אבקה להכנת תמיסה לזריקה

Composição:

BLEOMYCIN SULFATE 15000 IU/VIAL

Via de administração:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Tipo de prescrição:

מרשם נדרש

Fabricado por:

BAXTER ONCOLOGY GmbH, GERMANY

Grupo terapêutico:

BLEOMYCIN

Área terapêutica:

BLEOMYCIN

Indicações terapêuticas:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Data de autorização:

2020-09-30